Abstract: A ceramic coating includes: a ceramic layer; a molten-and-solidified layer formed on a surface of the ceramic layer; and a packed layer including ceramic packed in a crack which extends in a thickness direction of the molten-and-solidified layer.

Abstract: A method of manufacturing a honeycomb structure, the method including: a circumferential coat layer forming process of applying a circumferential coating material on a circumferential surface of a ceramic honeycomb structure to form a circumferential coat layer, the circumferential coat layer forming process including: a rotating process of matching an axial direction of the honeycomb structure; and an applying process of discharging the circumferential coating material to apply the circumferential coating material on the circumferential surface of the honeycomb structure that rotates, wherein in the applying process, a discharge speed of the circumferential coating material, calculated by Equation (1), discharged from the discharge nozzle is 50 to 120 mm/s, and Discharge speed V [mm/s]=Supplied amount q [g/s] of circumferential coating material÷(Density ? [g/mm3] of circumferential coating material×Area S [mm2] of discharge opening)??(1).

Abstract: The present invention relates to a process for the production of a phosphate containing fertilizer product, comprising the steps of providing a phosphate containing precipitate from a wastewater treatment process; separating water from the precipitate to provide a dewatered slurry cake; and optionally admixing a compound selected from nitrogen, potassium and additional phosphorous containing compounds. The present invention further relates to a fertilizer and uses.

Abstract: The problem of the present invention is to provide a magnesium hydroxide [Mg(OH)2] fertilizer to supply magnesium to plants without costs and time and to cultivate plants safely and economically using the magnesium hydroxide [Mg(OH)2] fertilizer. The above problem can be solved by effectively using laundry wastewater containing magnesium hydroxide [Mg(OH)2] after washing the laundry using magnesium material containing water and metal magnesium (Mg) as a main component.

Abstract: The present disclosure relates to an improved process for producing olefins from syngas. Raw material is treated to produce syngas comprising H2, CO and CO2. The ratio of H2 and CO in the syngas is 1:1. The syngas is contacted with at least one first catalyst to produce an intermediate stream comprising dimethyl ether (DME), and unconverted CO2, H2 and CO. The unconverted H2 and CO is recycled to a first catalyst section and a portion of the separated CO2 is recycled for producing the syngas. The remaining intermediate stream is contacted with at least one second catalyst to produce a second stream comprising olefins, H2O, methane, ethane, and propane. H2O, methane, ethane, and propane are separated to obtain the olefins. The separated methane, ethane, and propane are further recycled for producing the syngas. The CAPEX and OPEX of the improved process are reduced.

Abstract: Provided is a method for oligomerization of ethylene, and more particularly, a method for producing 1-hexene and 1-octene at a high selectivity under an ethylene atmosphere by inducing a remarkably improved catalytic activity while effectively reducing a production amount of polyethylene by introducing the oligomerization catalyst and a cocatalyst mixture containing at least two aluminums together and adjusting the kind of oligomerization catalyst and injection conditions thereof.

Abstract: Method of making BTX compounds including benzene, toluene, and xylene, including feeding heavy reformats to a reactor containing a composite zeolite catalyst. The composite zeolite catalyst includes a mixture of nanocrystalline Beta zeolite (Nano-Beta) comprising crystal size in the range of 10 to 40 nm and ZSM-5. The Nano-Beta, the ZSM-5, or both include one or more impregnated metals. The method further includes producing the BTX compounds by simultaneously performing transalkylation and dealkylation of the heavy reformate in the reactor. The composite zeolite catalyst is able to simultaneously catalyze both the transalkylation and dealkylation reactions.

Abstract: The present disclosure relates to a hydrocracking catalyst for preparing a C6-C9 light aromatic hydrocarbons having an increased BTX content from a polycyclic aromatic hydrocarbon, a method for preparing the same and a method for preparing a C6-C9 light aromatic hydrocarbons having an increased BTX content by using the same. More specifically, an effect of obtaining a C6-C9 light aromatic hydrocarbons having an increased BTX content with a high yield from the byproducts of oil refining and petrochemical processes, which contain polycyclic aromatic hydrocarbons such as naphthalene, alkylnaphthalene, etc., can be achieved by using a catalyst in which one or more metal selected from group VIII and one or more metal selected from group VIB are supported on a composite zeolite support of zeolite beta and zeolite ZSM-5.

Abstract: A process for producing one or more olefins is proposed in which a reaction input containing one or more paraffins is formed and in which a portion of the paraffin(s) present in the reaction input is converted by oxidative dehydrogenation into the olefin(s) to obtain a process gas, wherein the process gas contains at least the olefin(s), the unconverted paraffin(s), oxygen and carbon monoxide and wherein at least a portion of the process gas is subjected to a low temperature separation in which at an operating pressure level one or more gas fractions enriched in oxygen and carbon monoxide compared to the process gas are formed.

Abstract: Methods of making BTX compounds including benzene, toluene, and xylene include feeding heavy reformate to a reactor containing a composite zeolite catalyst. The composite zeolite catalyst includes a mixture of SSZ-33 and ZSM-5. The SSZ-33, the ZSM-5, or both comprise one or more impregnated metals. The method further includes producing the BTX compounds by simultaneously performing transalkylation and dealkylation of the heavy reformate in the reactor. The composite zeolite catalyst is able to simultaneously catalyze both the transalkylation and dealkylation reactions.

Abstract: Method of making BTX compounds including benzene, toluene, and xylene, including feeding heavy reformate to a reactor containing a composite zeolite catalyst. The composite zeolite catalyst includes a mixture of layered mordenite (MOR-L) comprising a layered or rod-type morphology with a layer thickness less than 30 nm and ZSM-5. The MOR-L, the ZSM-5, or both include one or more impregnated metals. The method further includes producing the BTX compounds by simultaneously performing transalkylation and dealkylation of the heavy reformate in the reactor. The composite zeolite catalyst is able to simultaneously catalyze both the transalkylation and dealkylation reactions.

Abstract: A method of making BTX (benzene, toluene, xylene) compounds by feeding a heavy reformate stream to a reactor, where the reactor includes a composite zeolite catalyst, that contains a mixture of a desilicated mesoporous mordenite and ZSM-5, and in which the desilicated mesoporous mordenite, the ZSM-5, or both, comprise one or more impregnated metals. The composite zeolite catalyst is able to catalyze the transalkylation reaction and the dealkylation reaction simultaneously to produce the BTX compounds.

Abstract: The present invention relates generally to methods and systems for removing oxygen from at least one product stream of a hydrocarbon oxidative dehydrogenation process. More specifically, in some embodiments, the oxidative dehydrogenation process is an ethane oxidative dehydrogenation process for producing ethylene, or a mixed alkane oxidative dehydrogenation process for producing ethylene and propylene, among other components.

Abstract: The disclosure relates to a method for hydrofluorination of an olefin of the formula: RCX?CYZ to produce a hydrofluoroalkane of formula RCXFCHYZ or RCXHCFYZ, wherein X, Y, and Z are independently the same or different and are selected from the group consisting of H, F, Cl, Br, and C1-C6 alkyl which is partially or fully substituted with chloro or fluoro or bromo; and R is a C1-C6 alkyl which is unsubstituted or substituted with chloro or fluoro or bromo, comprising reacting the olefin with HF in the liquid-phase, in the presence of SbF5, at a temperature ranging from about ?30° C. to about 65° C. and compositions formed by the process.

Abstract: A process of the type for producing chlorinated propanes by reacting carbon tetrachloride with ethylene within a tank reactor that includes a liquid reaction mixture and a headspace above the reaction mixture wherein ethylene gas diffuses from the liquid reaction mixture into the headspace while agitating the reaction mixture, the improvement comprising transferring ethylene within the headspace back into the reaction mixture through a conduit within the mixing device that agitates the reaction mixture.

Abstract: Continuous processes for making ethylene glycol form aldohexose-yielding carbohydrates are disclosed which enhance the selectivity to ethylene glycol.

Abstract: To provide a method for producing a Guerbet alcohol without necessity of the use of a solvent, capable of enhancing the conversion and the yield. A method for producing a Guerbet alcohol, including the following steps 1 to 3 in this order: step 1: preparing a liquid composition containing an aliphatic alcohol and a base; step 2: holding the liquid composition at 100° C. or more and 180° C. or less to thereby adjust a water amount in the liquid composition to less than 0.28% by mass; and step 3: setting the liquid composition to be more than 180° C.

Abstract: The present invention relates to an anhydrosugar alcohol composition having enhanced storage stability, and an anhydrosugar alcohol storage method, and more specifically, to an anhydrosugar alcohol composition having enhanced storage stability by comprising anhydrosugar alcohol and an amine-based additive; and to a method by which anhydrosugar alcohol having excellent quality may be provided by having the storing of the anhydrosugar alcohol performed under the existence of the amine-based additive, thereby remarkably enhancing the storage stability of the anhydrosugar alcohol.

Abstract: A method and a system for producing glycolic acid and/or glycolate from sustainable resources. A method for catalytic production of glycolic acid and/or glycolate including the step of: oxidation of a starting material including between 0.1-100 wt/wt % glycolaldehyde at a temperature of between ?10° C. and 100° C. with an oxidant in the presence of a metal-based catalyst including a catalytically active metal, which is selected from the group of palladium and platinum; or mixtures thereof.

Abstract: Neuroprotective compounds for reducing neurological damage due to cellular stress in an individual are of Formula 1: or an enantiomer, diastereomer, racemic mixture or a pharmaceutically acceptable salt thereof, wherein: Ar=aryl; Y=aryl substituent (ortho, meta, or para) selected from the group consisting of: alkyl, alkyloxy, alkylamino, R5R6N, and halo; X?O, N, or S; R?H, alkyl, aryl, OH, alkyloxy, aryloxy, NH2, alkylamino, R5R6N, or arylamino; R1 and R2=alkylcarbonyl, arylcarbonyl, alkyl, or H, individually; R3=arylCH?CH, alkylCH?CH, alkyl; R4?H, alkyl, or aryl; and R5 and R6=alkyl, individually. Methods of reducing neurological damage due to cellular stress in an individual include administering to the individual during or after the cellular stress a neuroprotective compound of Formula I in a therapeutically effective amount to restore synaptic function during or after the cellular stress.

Abstract: Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2-(3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and (c) reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one composition with ethylamine using a borohydride reducing agent to produce a fenfluramine composition. Also provided are compositions and pharmaceutical ingredients prepared according to the subject methods including a pharmaceutically acceptable salt of fenfluramine and having less than 0.2% by weight in total of trifluoromethyl regioisomers.

Abstract: The invention provides a process for preparing farnesylamines by reacting ?-farnesene with one or more amines in the presence of a transition metal catalyst from transition group 10 at a temperature in the range from 60 to 150° C.

Abstract: The present invention relates to a novel method for preparing (S)—N1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrochloride.

Abstract: Ethyl benzyl quaternaries having superior anti-fungal properties versus their benzyl quaternary analogs. The ethylbenzyl amidoamine quaternaries of the present invention are easily produced without significant waste and with minimal capital, while possessing improved antimicrobial properties.

Abstract: The present invention relates to the reduction of polycyano compounds to produce polyamines, in particular diaminoacetal and diaminoketal compounds, and their use as curing agents in epoxy resin compositions. The reduction with molecular hydrogen can be carried out using a metal catalyst selected from GROUP VIII and a catalytic promoter. The reduction can include anhydrous or aqueous ammonia. The reaction can be carried out in continuous and batch modes with catalyst and solvent recycling. The epoxy resin composition consisting of an epoxy resin and a polyamine curing agent that can be used in fiber-reinforced composite materials, coating materials, and the like.

Abstract: The invention relates to lipid compounds of formula f(1) and their pharmaceutically acceptable salts for the prevention and/or treatment of ophthalmic disorders such as retinal degenerative disorders and ocular inflammatory diseases: (I) (wherein R1 is either a C9 to C22 alkyl group, or a C9 to C22 alkenyl group having from 1 to 6 double bonds; R2 is selected from the group consisting of a halogen atom, a hydroxy group, an alkyl group, an alkoxy group, an alkylthio group, a carboxy group, an acyl group, an amino group, and an alkylamino group; R3 is a hydrogen atom, or a group R2; R4 is a carboxylic acid or a derivative thereof; and X is methylene (—CH2—), or an oxygen or sulfur atom).

Abstract: The present invention relates to compounds having a benzotropolone core, and compositions containing said compounds acting as ATG4B inhibitors, thereby inhibiting autophagy. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.

Abstract: The present invention relates to a continuous process for the preparation of N-alkyl-nitratoethylnitramines (e.g. NENA compounds, DINA).

Abstract: Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.

Abstract: A method for treating phytophotodermatitis including the steps of applying an isothiocyanate functional surfactant to an area affected by phytophotodermatitis, wherein said isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

Abstract: The sulfonium salt does not contain a toxic metal and exhibits higher cationic polymerization performance and crosslinking performance than a tetrakis(pentafluorophenyl)borate salt. The heat- or photo-acid generator contains the sulfonium salt. The sulfonium salt is formed of a sulfonium cation selected from a group represented by general formulas (1), (9), (10) and (11) described below and a gallate anion represented by formula (a). The heat- or photo-acid generator contains the sulfonium salt. The heat- or energy ray-curable composition contains the acid generator and a cationically polymerizable compound. A cured product can be obtained by curing the same.

Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Abstract: Compounds of Formula I are disclosed and methods of treating viral infections with compositions comprising such compounds.

Abstract: Provided are a diamine-based compound having a certain formula and an organic light-emitting device including the same.

Abstract: The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (II) or a pharmaceutically acceptable sat thereof, wherein R1, R2, R3, R4, R5, R8, R9, R10, R12, Z, Y and m are as defined herein.

Abstract: Provided herein is a process for the preparation of 4-((6-bromopyridin-3-yl)oxy)benzonitrile.

Abstract: The present invention provides compounds for the treatment of a bacterial infection. Additionally, the present invention provides compositions and methods for using these compounds and compositions in the treatment of a bacterial infection in a subject.

Abstract: Disclosed is hydroxamic acid compounds of Formula (I) set forth herein. Also disclosed are a pharmaceutical composition containing such a compound and a method of using the compound for treating a condition associated with histone deacetylase 6.

Abstract: Provided herein are optionally substituted benzoimidazol-1,2-yl amides, pharmaceutical compositions comprising a therapeutically effective amount of such compounds and a pharmaceutically acceptable excipient, and methods of treating Kv7 associated diseases, such as, epilepsy, amyotrophic lateral sclerosis, various types of pain, hyperexcitability, a dyskinesia, dystonia, mania and tinnitus with such compounds and pharmaceutical compositions.

Abstract: The present invention relates to novel pyrimidine compounds, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer and inflammatory disease. The novel pyrimidine compounds according to the present invention remarkably inhibits activity of DRAK that inhibits signal systems of TGF-?, which is known to suppress cancer growth, and thus the novel pyrimidine compounds can be used as a pharmaceutical composition for preventing or treating cancer and can be used as a pharmaceutical composition for preventing or treating inflammatory disease.

Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have one of the following structures (I), (II) or (III): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5a, R5b, R6, A, B, G1, G2, L1, L2, m1, m2, n, x, y, X and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Abstract: A process for preparing clomazone is provided, the process comprising reacting 4,4-dimethyl-3-isoxazolidinone with 2-chlorobenzyl chloride in an aqueous medium in the presence of a base, in particular an alkali metal hydroxide. A method for preparing clomazone is also disclosed, the method comprising (a) crystallizing clomazone from solution in an organic solvent; and (b) isolating the resulting crystals. N-benzene is a particularly suitable solvent. Further, there is provided Form I crystalline 2-[(2-chlorophenyl)methyl]-4,4-dimethyl-3-isoxazolidinone (clomazone), wherein the polymorph Form I is characterized by at least one of the following properties: (i) an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2?(+/?0.20° ?) at one or more of the following positions: about 10.63, 16.07, 18.08, 19.11, 19.34, 21.20, 24.78 and 28.80; and (ii) an infrared (IR) spectrum having a characteristic peak: at about 2967 and 2870 cm?1.

Abstract: Provided are a crystal and salt of an m-dihydroxybenzene derivative represented by formula (I), a manufacturing method thereof, and an application of the crystal in preparing a pharmaceutical product for treating a HSP90-mediated disease.

Abstract: A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in therapy, e.g. in the treatment of autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders.

Abstract: Compounds of the formula (I), wherein the substituents are as defined as claim 1, useful as a pesticides, especially as fungicides.

Abstract: Disclosed is an aryl hydrocarbon receptor modulator of formula (I), and a pharmaceutically acceptable salt thereof, wherein R? is H, CN, CH2(OH)R0, CmH2m+1, CnH2n?1, CnH2n?3, two Ra are independently H or two Ra together form =0 or ?N—W3—R1; A is a C6 to C10 aromatic ring unsubstituted or substituted with 1 to 3 R, or a C2-C10 heteroaromatic ring interrupted by 1 to 5 heteroatoms selected from N, 0, and S or a 4 to 7 membered nonaromatic heterocyclic ring containing C?N and interrupted by 1 to 3 heteroatoms selected from N, 0, and S, with either one unsubstituted or substituted with 1 to 3 R; Q is R, or is a C6 to C10 aromatic ring or a C2 to C10 heteroaromatic ring unsubstituted or substituted with 1 to 3 R and interrupted by 1 to 5 heteroatoms selected from N, 0, and S; and R is RC which is C-attached or RN which is N-attached.

Abstract: A process for the preparation of 2,2,5,5-tetramethyltetrahydrofuran (TMTHF) includes contacting a TMTHF precursor with a solid catalyst, where the TMTHF precursor is 2,5-dimethylhexane-2,5-dioland/or 2,5-dimethyl-4-hexen-2-ol, and where the solid catalyst is a beta zeolite. TMTHF produced by the process may be used as a solvent.

Abstract: The disclosure relates to an efficient process for the production of a furan derivative from C5 and/or C6 sugars. The process utilizes a water immiscible organic solvent system comprising at least one alkyl phenol and at least one alkylated naphthalene.

Abstract: This invention relates to malienated derivatives made from maleic anhydride, functionalized monomers, and one or more additional reagents, e.g., an oxygen-containing reagent (e.g., alcohol, polyol), a nitrogen-containing reagent (e.g., amine, polyamine, aminoalcohol), a metal and/or a metal compound. The invention relates to lubricants, functional fluids, fuels, dispersants, detergents and functional compositions (e.g., cleaning solutions, food compositions, etc.

Abstract: The present application relates a crystal of a compound represented by Formula (I), a salt thereof, and a crystal of the salt thereof, a method for preparing the crystal of the compound represented by Formula (I), the salt thereof, and the crystal of the salt thereof, a crystal comprising the compound represented by Formula (I), a crystal composition comprising the crystal of the salt thereof, a pharmaceutical composition thereof, and medical uses thereof.